Skip to main content

Table 4 Summary of most frequent adverse events by organ system, number of dogs affected

From: Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up

Category of adverse events

High dose, N = 66 Number of dogs (dogs with likely treatment relation)

Low dose, N = 61 Number of dogs (dogs with likely treatment relation)

Significancea, high vs. low-dose group (dogs with likely treatment relation)

Any

57 (39)

50 (25)

p = 0.497 (p = 0.041)

Central nervous systemb

48 (33a)

32 (19a)

p = 0.018 (p = 0.031)

Gastro-intestinal system

32 (8)

25 (2)

p = 0.396 (p = 0.065)

Musculoskeletal system

12 (10)

8 (3)

p = 0.443 (p = 0.057)

Respiratory system

7 (4)

8 (4)

p = 0.662 (p = 0.908)

General

5 (2)

5 (2)

p = 0.897 (p = 0.936)

Urogenital tract

4 (1)

5 (1)

p = 0.639 (p = 0.956)

Other systems

14 (10)

15 (3)

p = 0.650 (p = 0.057)

  1. aBased on the two-sided chi-square test for the equality of proportions from two independent samples
  2. bMainly seen during first weeks of treatment